Pueraria mirifica Studies i
Pueraria mirifica increases bust size
Thai biologist claims tuber can enlarge bust size
Asian Economic News, Jan 11, 1999 BANGKOK, Jan. 4 Kyodo
A Thai biologist Monday claimed that he has proved that a plant stem, known locally as ”kwao krua,” can produce the female sex hormone estrogen in women and increase their bust size. Wichai Cherdshewasart, associate professor at Chulalongkorn University who said he spent almost a year conducting research on the kwao krua tuber (Pueraria mirifica), claimed that tests showed one woman’s bust grew 2.5 centimeters in five days through using the substance. The biologist said he has applied for a patent to manufacture medicine from kwao krua and is now planning its production for the drug industry. But results are not guaranteed, said Wichai, as about 20% of test cases showed no response. ”It depends on your health. If you are in good shape, between 20 and 45 years of age and have a rather big body structure, you will get good results,” Wichai said. ”It is impossible for a thin lady to enlarge her bust from 75 cm to 90 cm by taking kwao krua (Pueraria mirifica).” The effects of the tuber are the stuff of legend, as long ago in the northern province of Chiang Mai, the plant stem had the reputation of producing a rejuvenating effect on the elderly.
According to the legend, an old lady began to menstruate again after regularly taking medicine made of kwao krua, while an impotent old man sired offspring thanks to the magic tuber. Scientists spent more than 10 years in their quest to track down the legendary kwao krua. In February 1947, they finally identified it as Pueraria mirifica. Wichai recommended that in some cases, women should drink milk while taking kwao krua. One thin lady enlarged her 72.5-cm bust to 77.5-cm within a month by drinking at least a liter of milk per day, he said. Besides enlarging bust size, the tuber can also widen hips, soften skin and darken hair for those who turn gray early, according to Wichai. Once the Thai Ministry of Public Health endorses the patent, he said, variations of the drug will be developed for menopausal women who suffer from hormone drain. ”My idea is something like refilling a woman’s hormones to adjust glandular organic function,” he said.
Pueraria mirifica and Breast cancer
Pueraria mirifica decreases breast tumor incidence
Pre-treatment with phytoestrogen-rich plant decreases breast tumor incidence and exhibits lower profile of mammary ERα and ERβ
Source: Maturitas Volume 58, Issue 2, 20 October 2007, Pages 174-181
Wichai Cherdshewasart, Rattana Panriansaen and Porntipa Picha. Department of Biology, Faculty of Science, Chulalongkorn University, Phyathai Road, Patumwan, Bangkok 10330, Thailand Program of Biotechnology, Faculty of Science, Chulalongkorn University, Phyathai Road, Patumwan, Bangkok 10330, Thailand
Section of Experimental Oncotherapy, Research Division, National Cancer Institute, Ministry of Public Health, RamaVI Road, Ratchathewi, Bangkok 10400, Thailand
Received 19 May 2007; revised 2 August 2007; accepted 9 August 2007. Available online 17 September 2007.
Abstract
Objective
Phytoestrogens have been reported to exhibit antiproliferation to human breast cancer cells in vitro. We tested the phytoestrogen-rich, Pueraria mirifica against rat breast cancer induction in vivo.
Methods
The weanling female Spargue–Dawley rats were pretreated with P. mirifica tuberous powder at a dosage of 0, 10, 100 and 1000 mg/kg BW/day for four consecutive weeks. Mammary tumor development was then induced with a single dose of 7,12-DMBA, 80 mg/kg BW, followed by a weekly examination for size and multiplicity of mammary tumors for 20 weeks and finally a necropsy. Mammary tissues were investigated for the virulence of tumor and also monoclonal antibody stained against ERα and ERβ.
Results
Pretreatment of 1000 mg/(kg BW day) of Pueraria mirifica tuberous powder resulted in decreasing of the virulence of rat tumor development. The mammary tumor tissues exhibited lower profile of ERα and ERβ as well as ERα/ERβ.
Conclusion
Pueraria mirifica exhibited prevention of 7,12-DMBA-induced rat mammary tumors, with a proposed mechanism of strong competitive binding of its phytoestrogens to ERα and/or synthesis suppressor of ERα.
Keywords: Phytoestrogen ; Breast cancer ; Estrogen receptor ; 7,12-DMBA; Pueraria mirifica ; Isoflavonoid
Pueraria mirifica in treatment of menopausal syndrome
Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study
Publication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov’t
Journal of the Medical Association of Thailand (J Med Assoc Thai) 2007-Sep; vol 90 (issue 9) : pp 1720-6
PMID: 17957910 (status: MEDLINE) (last retrieval date: 12/14/2007)
Laemlertkittikul S., Chandeying V.
Affiliation: Department of Obstetrics and Gynecology, HatYai Regional Hospital, Songkhla 90110, Thailand.
OBJECTIVE:
To evaluate the efficacy comparison of Pueraria mirifica, name in Thai is Kwao Krua Khao, against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of perimenopuasal women with climacteric symptoms.
MATERIAL AND METHOD:
Perimenopausal women attending the Menopausal clinic of Hat Yai Regional Hospital were voluntarily recruited. The vasomotor symptoms such as hot flushes and night sweats, as well as other unpleasant symptoms, urogenital and psychological symptoms, were also assessed. Patients were voluntarily enrolled and randomly received daily 50 mg raw material of PM, Group A, or daily 0.625 mg of conjugated equine estrogen (CEE) with/without 2.5 mg of medroxyprogesterone acetate (MPA), Group B, depend on non-hysterectomized/hysterectomized condition.
RESULTS:
Seventy-one patients were enrolled. Eleven of those were excluded for failing to complete the initial work-up and follow-up. Sixty cases were evaluated, 30 cases in Group A and 30 cases in Group B. After medication, the mean of modified Greene climacteric scale (MGCS) in Group A/Group B had decreased from 29.0/32.26 to 17.86/18.1, 12.56/9.57 and 9.9/8.16 at 1-, 3-, and 6- month respectively. The clinical satisfaction using MGCS was not statistically significant between Pueraria mirifica (Group A) and CEE with/without MPA (Group B) in the alleviation of climacteric symptoms (p-value > 0.05). There were no statistically significant changes of three serum markers: estradiol, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) between both groups.
CONCLUSION:
Pueraria mirifica, containing phytoestrogens, has estrogenic effect as similar as CEE, and can alleviate the climacteric symptoms in perimenopausal women. Pueraria mirifica demonstrates great promise in the treatment of climacteric symptoms. However, optimal doses should be clinically assessed to meet appropriate individual responses.
Pueraria mirifica studies
Thai biologist claims tuber can enlarge bust size
Pueraria mirifica decreases breast tumor incidence
Pueraria mirifica reduce Breast cancer risks
Research and Study on Pueraria mirifica
A national – level committee is set up to push for export – processing.
Pueraria mirifica, a phytoestrogen-rich herb, prevents bone loss in orchidectomized rats.
Finished herbal product as an alternative treatment for menopausal symptoms in climacteric women.
Beneficial Estrogenic Effects of Pueraria mirifica on Vaginal Health in Postmenopausal Women
Medical Reports on the Effectiveness of Phytoestrogens
Pueraria mirifica clinical study in Premenopausal women
Case Control Study of Phytoestrogens and Reduction in breast-cancer risk
